S121: REDUCED RATE OF VASO-OCCLUSIVE CRISES (VOCS) IN PATIENTS (PTS) WITH SICKLE CELL DISEASE (SCD) TREATED WITH CRIZANLIZUMAB FOR 12 MONTHS: RESULTS FROM A REAL-WORLD, MANAGED ACCESS PROGRAM (MAP)

অনুরূপ উপাদানগুলি

• P1491: REAL-WORLD INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
  অনুযায়ী: Silva-Pinto, A. C., অন্যান্য
  প্রকাশিত: (2022)
• O-04: INCIDENCE OF VASO-OCCLUSIVE CRISES IN PATIENTS WITH SICKLE CELL DISEASE (SCD) AND A HIGH BASELINE DISEASE BURDEN TREATED WITH CRIZANLIZUMAB IN A REAL-WORLD SETTING: RESULTS FROM A MANAGED ACCESS PROGRAM (MAP)
  অনুযায়ী: A., SILVA-PINTO, অন্যান্য
  প্রকাশিত: (2022)
• P-Selectin Blockade in the Treatment of Painful Vaso-Occlusive Crises in Sickle Cell Disease: A Spotlight on Crizanlizumab
  অনুযায়ী: Karki, Nabin Raj, অন্যান্য
  প্রকাশিত: (2021)
• The European Medicines Agency Review of Crizanlizumab for the Prevention of Recurrent Vaso-Occlusive Crises in Patients With Sickle Cell Disease
  অনুযায়ী: Delgado, Julio, অন্যান্য
  প্রকাশিত: (2021)
• Profile of crizanlizumab and its potential in the prevention of pain crises in sickle cell disease: evidence to date
  অনুযায়ী: Riley, Tanya R, অন্যান্য
  প্রকাশিত: (2019)